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Objectives: 1) To measure and compare the time required to perform (pTUG) and the time required to imagine
(iTUG) the Timed Up & Go (TUG), and the time difference between these two tasks (i.e., TUG delta time) in older
adults with cognitive decline (i.e., mild cognitive impairment (MCI) and mild-to-moderate Alzheimer disease and
related disorders (ADRD)) and in cognitively healthy individuals (CHI); and 2) to examine any association between
the TUG delta time and a cognitive status.
Methods: Sixty-six participants (24 CHI, 23 individuals with MCI, and 19 individuals with ADRD) were recruited in
this cross-sectional study. The mean and standard deviation of the pTUG and iTUG completion times and the
TUG delta time, as well as age, gender, and Mini-Mental State Examination (MMSE) scores were used as outcomes.
Participants were separated into three groups based on the tertilization of TUG delta time: lowest (<13.6%; n = 22;
best performance), intermediate (13.6-52.2%; n = 22), and highest tertile (>52.2%; n = 22, worst performance).
Results: Fewer CHI were in the group exhibiting the highest tertile of TUG delta time compared to individuals
with lowest and intermediate TUG delta times (p = 0.013). Being in the highest tertile of the TUG delta time was
associated with cognitive decline in the unadjusted model (p = 0.012 for MCI, and p = 0.021 for mild-to-moderate
ADRD). In the multivariate models, this association remained significant only for individuals with MCI (p = 0.019
while adjusting for age and gender; p = 0.047 while adjusting for age, gender, and MMSE score; p = 0.012 for the
stepwise backward model).
Conclusions: Our results provide the first evidence that motor imagery of gait may be used as a biomarker of
MCI in older adults.
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There is growing evidence that cognitive decline results
in the deterioration of gait patterns [1-3]. Though it is
commonly associated with the later stages of dementia,
a decline in gait performance may also be detected much
earlier. Some go so far as to suggest that this decline can
be detected before the prodromal stage of mild cognitive
impairment (MCI) [1-8]. In either case, there is an obvi-
ous association between gait disorders and the impair-
ment of the highest levels of gait control [4-8].
The diagnosis of MCI is based on a comprehensive
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reproduction in any medium, provided the orcognitive domains, such as episodic memory and execu-
tive function, combined with blood tests and brain
imaging [1-5]. However, this diagnostic process is time-
consuming, expensive and does not conclusively demon-
strate that an individual has MCI. Since interventions
appear to be more effective in early stages of the disease,
improving early diagnosis of dementia at the prodromal
stage of MCI is an important research goal. Recently, the
use of biomarkers has been proposed to facilitate the early
diagnosis of dementia [9]. Biomarkers are defined as indi-
cators of a disease process, and their complementary use
to classical neuropsychological tools is essential to this aim
[9]. For example, specific proteins in the cerebrospinal fluidal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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disease (AD) and so serve as biomarkers when screening
for that condition [9]. However, the main limitation of CSF
biomarkers is the compulsory invasive examination, often
referred to as CSF tapping. If a clear link can be established
between spatio-temporal gait parameters and the motor
disorders of early-stage dementia, an alternative, non-
invasive biomarker could be implemented. Such a bio-
marker could be more easily assessed in clinical practice
and could serve to improve the prediction accuracy of
these screening procedures, particularly those related to
AD [10].
Motor imagery is the mental simulation of a given action
without its actual execution. It is a method used clinically
to explore the highest level of gait control [11,12]. Recently,
a mental chronometry approach was used to show that
cognitive performance, executive functioning in particular,
contributes to the temporal correspondence between exe-
cuting and imaging gait in patients with dementia, schizo-
phrenia, and multiple sclerosis [13-15]. This approach
showed that older adults with cognitive decline executed
the imagined Timed Up & Go test (iTUG) more quickly
than the same task actually performed (pTUG), although
this was not the case in healthy younger adults [11].
The pTUG test offers a basic assessment of a patient’s
functional mobility by measuring the time while standing
up, walking, turning, and sitting down. This test has been
used to evaluate gait and balance performance in previous
studies/the clinical environment/wherever [16].
Similar to gait motor imagery, gait variability also re-
flects the functionality of the highest level of gait control.
Higher gait variability was reported for individuals with
MCI but not for individuals with AD [2]. This suggests
that higher gait variability in individuals with MCI may re-
flect an early dysfunction of the cortical sensorimotor con-
trol of gait involving the hippocampus [15,2]. Therefore,
we hypothesized that a poor time correspondence between
pTUG and iTUG completion times will be observed in in-
dividuals with MCI rather than in those with ADRD or in
cognitively healthy individuals (CHI). This conclusion was
reached because individuals with MCI are suspected to
have more difficulties imagining gait than actually walking.
The objectives of this cross-sectional study were 1) to
measure and to compare pTUG and iTUG completion
times as well as the time difference between these two
motor tasks (i.e., TUG delta time) in older adults with and
without cognitive decline; and 2) to examine whether
there was an association between the TUG delta time and
the cognitive status (e.g., CHI, MCI, ADRD).
Methods
Participants
From December 2009 until November 2010, 66 par-
ticipants (24 CHI [mean age 68.8 ± 4.6 years; meanMini-Mental State Examination score (MMSE) score
29.0 ± 1.2; 79.2% female], 23 individuals with MCI [mean
age 70.8 ± 4.6 years; MMSE score 27.8 ± 1.3; 65.2% female]
and 19 individuals with mild-to-moderate ADRD [mean
age 80.1 ± 4.3 years; MMSE score 20.4 ± 4.7; 89.5% female])
were recruited in the "GAIT" (Gait and Alzheimer Inter-
action Tracking) study, which is a cross-sectional study
designed to compare gait characteristics of CHI and partic-
ipants with MCI and ADRD. The data collection proced-
ure has been described elsewhere in detail [2,17]. In brief,
all participants were referred for evaluation of memory
complaints at the memory clinic of Angers University
Hospital, France. The eligibility criteria were: age 65 years
and over, ambulatory, an adequate understanding of
French, and no history of acute medical illness in the past
month. For the present analysis, exclusion criteria were:
severe ADRD (i.e., MMSE ≤ 9 [18]), extrapyramidal ri-
gidity of the upper limbs, neurological and psychiatric
diseases other than cognitive impairment, severe medical
conditions affecting walking, inability to walk 15 minutes
unassisted, or the presence of depressive symptoms defined
by a 4-item Geriatric Depression Scale score above 1 [19].
Participants in the study were included after having
given their written informed consent for research. The
study was conducted in accordance with the ethical
standards set forth in the Helsinki Declaration (1983)
and the entire study protocol was approved by the local
Ethical Committee of Angers, France.
Neuropsychological and physical assessment
A neuropsychological assessment was performed on
each participant during a face-to-face examination by a
neuropsychologist. The following standardized tests were
used to probe several aspects of cognitive function:
MMSE [18], Frontal Assessment Battery (FAB) [20],
Alzheimer's Disease Assessment Scale–Cognitive sub-
scale (ADAS-cog) [21], Trail Making Test (TMT) parts A
and B [22], French version of the Free and Cued Selective
Reminding Test [23,24], and Instrumental Activities of
Daily Living scale (IADL) [25]. The diagnoses of MCI
and ADRD were made during multidisciplinary meetings
involving geriatricians, neurologists, and neuropsycholo-
gists of Angers University Memory Clinic, and they were
based on the aforementioned neuropsychological tests,
physical examination findings, blood tests, and brain
magnetic resonance imaging (MRI). MCI was diagnosed
according to the criteria detailed by Winblad et al. [26].
Participants with any form of MCI, be it amnesic or non-
amnesic and affecting single or multiple domains, were
included in this study. The diagnosis of ADRD followed
the DSM-IV and NINCDS/ADRDA criteria [27]. Mild-to-
moderate stages of ADRD were defined by a MMSE score
greater than or equal to 10. Participants who had neither
MCI nor ADRD and who had normal neuropsychological
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tively healthy.
Gait assessment
This study used the TUG test described by Podsiadlo
and Richardson [16]. Participants were asked to perform
the TUG (pTUG) at their self-selected pace in a well-lit
environment. Participants were permitted to use their
walking aid if needed. All participants completed one
trial of the pTUG and then one trial of the iTUG while
sitting on a chair. Times for each condition were re-
corded with a stopwatch to the nearest 0.01 second. Be-
fore testing, a trained evaluator gave standardized verbal
instructions regarding the test procedure. For the pTUG,
participants were initially seated and were allowed to use
the armrests to stand up if necessary. The pTUG partici-
pants were instructed to walk three meters, to turn
around, to walk back to the chair, and lastly to sit down.
For the iTUG, participants remained seated in the chair
and were instructed to imagine doing the TUG and to
say “stop” out loud when they were finished. Participants
could choose to do the iTUG with their eyes opened or
closed. The stopwatch was started on the command
“ready-set-go” and stopped when the participant pro-
nounced the word “stop”.
Outcome variables
The main outcome variables were: 1) the mean ± SD of
the time to completion for both the pTUG and iTUG; 2)
the mean ± SD of the TUG delta time, which was calcu-
lated according to the following formula: [(pTUG–
iTUG) / (pTUG + iTUG / 2)] x 100; 3) the mean ± SD of
the participants’ age; 4) sex of the participants; 5) the
cognitive status of the participants as either CHI, MCI,
or mild-to-moderate ADRD; and 6) the global cognitive
performance estimated by the mean ± SD of the MMSE
score.
Statistics
The participants’ characteristics were summarized using
either mean ± SD or frequencies and percentages, as ap-
propriate. Participants were separated into 3 groups
based on the tertilization of the TUG delta time: lowest
(<13.6%; n = 22; best performance), intermediate (13.6-
52.2%; n = 22), and highest tertile (>52.2%; n = 22, worst
performance). Between-group comparisons were per-
formed using Kruskal-Wallis, Mann–Whitney, or Chi-
square tests, as appropriate. Univariate and multiple
logistic regression analyses were performed to specify
the association between the worst tertiles of TUG (i.e.,
the highest tertile of TUG delta time, the highest tertile
of pTUG [i.e., >10.9 seconds] and the lowest tertile of
iTUG [i.e., <6.0 seconds]) used as dependent variables
and the cognitive status (MCI and mild-to-moderateADRD, compared to CHI as reference level) used as in-
dependent variables adjusted for baseline characteris-
tics (i.e., age, gender and MMSE score). P-values that
were less than 0.05 were considered statistically signifi-
cant. All statistics were performed using SPSS (version
19.0; SPSS, Inc., Chicago, IL).
Results
Comparisons among groups showed that individuals
with the worst performance, defined as being in the
highest tertile for TUG delta time, were older than those in
the intermediate (p = 0.019) and lowest tertiles (p = 0.026)
(Table 1). They had also a lower MMSE score com-
pared to those in the intermediate tertile (p < 0.001)
and those in lowest tertile (p = 0.016). There were
fewer CHI in the highest tertile group than in the low-
est (p = 0.014) or intermediate (p = 0.004) groups. In
addition, individuals in the highest tertile group of TUG
delta time had worse TUG performance compared to the
lowest and the intermediate groups (all p-values < 0.006)
across all of the examined criteria (i.e., pTUG, iTUG,
and TUG delta time). Similar results were shown with
the comparison between the lowest and the intermedi-
ate tertile groups (all p-values <0.001) except for the
pTUG completion time, for which there was no differ-
ence (p = 0.354). As shown in Table 2, the logistic re-
gression models indicated that the highest tertile of
TUG delta time was associated with cognitive impair-
ments in the unadjusted model (p = 0.012 for MCI, and
p = 0.021 for ADRD). Adjusted models showed that this
association remained significant only with the MCI status
(p = 0.019 while adjusting for age and gender; p = 0.047
for the fully adjusted model; p = 0.012 for the stepwise
backward model). Furthermore, the MMSE score was
also associated with the highest tertile of TUG delta time
in the stepwise backward logistic regression (p = 0.009).
While considering the highest tertile of pTUG perform-
ance as a dependent variable, an association was found
with mild-to-moderate ADRD (p = 0.021) in the un-
adjusted regression model, but it disappeared in the
multivariate models. Stepwise backward modelling showed
an association only with MMSE score (p = 0.002). Lastly, a
significant association was shown between the lowest ter-
tile of iTUG performance and MCI status in the stepwise
backward model (p = 0.013).
Discussion
The main finding of this study is that individuals with
MCI executed the iTUG trial faster than the pTUG trial
in comparison to individuals with CHI.
Our findings are in concordance with a previous study
showing that cognitive decline was related to the time
difference between the pTUG and iTUG completion
times [13]. In comparison to this previous study, we
Table 1 Characteristics of participants separated into 3 groups according to the tertiles of TUG delta time* (n = 66)
Tertiles of TUG delta time P-Value†
Lowest
(n = 22)
Intermediate
(n = 22)
Highest
(n = 22)
Overall Lowest versus
intermediate
Lowest versus
highest
Intermediate versus
highest
Age (years), mean ± SD 71.4 ± 5.9 71.1 ± 6.4 76.3 ± 7.0 0.028 0.621 0.026 0.019
Female, n (%) 14 (63.6) 15 (68.2) 15 (68.2) 0.934 - - -
Cognitive status, n (%)
CHI 10 (45.5) 12 (54.5) 2 (9.1) 0.013 0.650 0.014 0.004
MCI 6 (27.3) 7 (31.8) 10 (45.5) 0.173 - - -
Mild-to-moderate ADRD 5 (22.7) 3 (13.6) 6 (27.3) 0.335 - - -
MMSE score (/30), mean ± SD 26.5 ± 4.6 28.2 ± 2.3 23.6 ± 5.2 0.001 0.168 0.016 <0.001
Timed Up & Go test, mean ± SD
pTUG (seconds) 9.8 ± 2.6 9.1 ± 1.6 15.0 ± 9.3 <0.001 0.354 0.005 <0.001
iTUG (seconds) 10.1 ± 2.9 6.6 ± 1.3 5.5 ± 1.9 <0.001 <0.001 <0.001 0.018
TUG Delta time* (%) −2.3 ± 15.8 31.2 ± 11.1 84.9 ± 25.5 <0.001 <0.001 <0.001 <0.001
CHI: Cognitively healthy individual.
MCI: Mild cognitive impairment.
ADRD: Alzheimer disease and related disorders.
MMSE: Mini-Mental status examination.
TUG: Timed Up & Go test.
pTUG: performed TUG.
iTUG: imagined TUG.
n: number of participants.
*: Calculated from the formula: delta time = [(pTUG–iTUG)/(pTUG + iTUG)/2] ×100.
†: Between-group comparisons were performed using Kruskal-Wallis, Man-Whitney, or Chi-square tests, as appropriate.
P significant (<0.05) indicated in bold.
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and mild-to-moderate ADRD) using a mental chronom-
etry approach. The association found between the worst
(i.e., highest) TUG delta time and the MCI status con-
firmed the fact that abnormal gait control estimated
from pTUG and iTUG trials should be considered as an
early biomarker of dementia, as suggested in two re-
cently published studies [2,3]. The first report outlined
an association between MCI status and higher gait vari-
ability [2]. Gait variability is defined as fluctuations in
stride-to-stride intervals and reflects the cortical control
of gait [4-8]. Increased gait variability reported in de-
mented individuals is usually interpreted as abnormal
gait control provoked by cognitive impairment [4,6,8].
Using a similar study design and the same groups of
participants, the increased gait variability observed of
individuals in a past study with MCI was explained by
cortical cognitive dysfunction with subsequent cortical
misprocessing of sensorimotor information [2]. These
factors combined to produce higher gait variability [2].
Verghese et al. [3], showed that the combination of
memory complaints with slower gait, defined as the
Motor Cognitive Risk (MCR) syndrome, was predictive
of a higher risk of dementia. This study provided pre-
liminary support for a motor-based MCR syndrome
that could identify older individuals at high risk for
transitioning to dementia. The result of the present
study agreed with these two prior reports [2,3]. Indeed,the high TUG delta time exhibited by individuals with
MCI could be considered as an early biomarker of cog-
nitive decline, similar to high gait variability for the
MCR syndrome. In this study, however, we used a new
and complementary approach based on mental chron-
ometry that is designed to be implemented in clinical
practice. Using functional magnetic resonance imaging,
previous studies showed that motor imagery of gait ac-
tivated several brain areas including the supplementary
motor area, the bilateral precentral gyrus, the left dor-
sal premotor cortex, and the cingulated motor area
[28-30]. The specific involvement of the hippocampus
was also recently found in an fMRI study comparing
mental imagery of gait between young and older adults
[31]. Different brain areas such as the prefrontal cortex,
Brodmann area 6 and the posterior supplementary motor
cortex in particular, seem to be predominantly related to
the MCI status [28,30,31]. Following the previous observa-
tions, it can be postulated that individuals with MCI may
also have deficits in those regions which may disturb their
motor imagery ability. The latter point could explain the
positive association between MCI status and delta time re-
ported in our study.
Our findings also highlight the fact that MMSE score
is inversely related to change in TUG delta time, which
is in accordance with a previous study [2]. It should
also be noted that the high delta time was specifically
related to the MCI status, even though ADRD
Table 2 Univariate and multiple logistic regression models showing the association between a) the highest tertile of
TUG delta time*, b) the highest tertile of pTUG and c) the highest tertile of iTUG (dependent variables) and cognitive
status (independent variable) adjusted for participants' characteristics (n = 66)
Model 1 Model 2 Model 3 Model 4
OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value
a) TUG delta time
CHI 1.00 (Ref†) 1.00 (Ref†) 1.00 (Ref†)
MCI 8.5 [1.6;44.8] 0.012 8.6 [1.4;51.8] 0.019 6.8 [1.1;45.3] 0.047 5.9 [1.5;23.6] 0.012
Mild-to-moderate ADRD 8.3 [1.4;49.6] 0.021 2.8 [0.3;29.8] 0.394 0.4 [0.0;13.4] 0.594 - - -
Age 1.1 [1.0;1.3] 0.190 1.1 [1.0;1.3] 0.117 - - -
Female gender 1.4 [0.3;5.9] 0.635 1.3 [0.3;6.1] 0.769 - - -
MMSE 0.8 [0.6;1.1] 0.136 0.8 [0.6;0.9] 0.009
b) pTUG
CHI 1.00 (Ref†) 1.00 (Ref†) 1.00 (Ref†)
MCI 0.5 [0.1;2.1] 0.305 0.7 [0.7;2.1] 0.260 0.2 [0.0;1.4] 0.104 - - -
Mild-to-moderate ADRD 5.4 [1.3;22.6] 0.021 1.3 [0.2;10.4] 0.807 0.1 [0.0;3.0] 0.188 - - -
Age 0.8 [1.0;1.3] 0.0.75 1.2 [1.0;1.4] 0.055 - - -
Female gender 1.5 [0.3;6.8] 0.611 1.2 [0.2;6.1] 0.804 - - -
MMSE 0.7 [0.5;1.0] 0.049 0.7 [0.6;0.9] 0.002
c) iTUG
CHI 1.00 (Ref†) 1.00 (Ref†) 1.00 (Ref†)
MCI 3.5 [1.0;12.5] 0.056 4.1 [0.9;18.3] 0.060 4.1 [0.8;20.3] 0.086 4.4 [1.4;14.3] 0.013
Mild-to-moderate ADRD 0.6 [0.1;3.8] 0.617 0.9 [0.1;9.1] 0.900 0.3 [0.0;12.0] 0.541 - - -
Age 0.7 [0.9;1.1] 0.973 1.0 [0.9;1.1] 0.984 - - -
Female gender 1.3 [0.3;5.1] 0.718 1.4 [0.3;6.0] 0.646 - - -
MMSE 0.9 [0.6;1.2] 0.497 - - -
CHI: Cognitively healthy individual.
MCI: Mild cognitive impairment.
ADRD: Alzheimer disease and related disorders.
MMSE: Mini-Mental status examination.
TUG: Timed Up & Go test.
pTUG: performed TUG
iTUG: imagined TUG
OR: odds ratio.
CI: confidence interval.
n: number of participants.
Model 1: Unadjusted model.
Model 2: Adjusted on age and gender.
Model 3: Adjusted on all participants' characteristics.
Model 4: Stepwise backward model.
*: Calculated from the formula: delta time = [(pTUG–iTUG)/(pTUG + iTUG)/2] x100 with pTUG = performed TUG, and iTUG = imagined TUG.
†: CHI used as reference level.
P-value significant (<0.05) indicated in bold.
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lower MMSE score compared to the other groups. One
explanation is based on the fact that individuals with
moderate dementia experience difficulties walking, while
those with MCI may have more difficulties imagining gait
than actually performing the task. This would suggest a
lack of a dose–response between cognitive decline and
motor imagery, which would explain why only the stage
of MCI may be detected with TUG delta time. An alter-
native explanation could be that cognitive functions, and
consequently motor imagery ability, are too impaired inpeople with dementia to perform the iTUG trial cor-
rectly. Thus, the performance of iTUG trial is not readily
interpretable and thus not suitable for detecting the diag-
nosis of ADRD. In contrast with the previous study, we
did not find an effect of age on the TUG delta time.
There are two main explanations: first, we focused only
on older adults unlike the previous study that exam-
ined younger and older adults. Second, it is now well-
recognized that participants with cognitive decline present
greater gait impairments than those that occur naturally
through aging [1,3,15].
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design may limit the exploration of the association between
TUG performance and cognitive disorders. Second, re-
sidual potential confounders may still be present even
though we were able to control many characteristics likely
to modify this association.
Conclusion
These results provide the first evidence that the iTUG
test, which was designed to assess motor imagery of gait,
can be used as a biomarker of MCI in older adults.
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